Treatment failure in osteoporosis

[1]  P. Kann,et al.  Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass , 2012, Osteoporosis International.

[2]  C. Cooper,et al.  Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study , 2002, Osteoporosis International.

[3]  C. Cooper,et al.  Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta‐Analyses , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  S. Cummings,et al.  Which Fractures Are Associated with Low Appendicular Bone Mass in Elderly Women , 1991 .

[5]  M. Seibel,et al.  Use of Bone Turnover Markers in the Real World: Are We There Yet? , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  O. Johnell,et al.  Fracture risk following an osteoporotic fracture , 2004, Osteoporosis International.

[7]  Ego Seeman,et al.  Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. , 2004, Bone.

[8]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[9]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  Fran Harris,et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.

[12]  A. Díez-Pérez,et al.  Risk factors for prediction of inadequate response to antiresorptives , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  R. Lindsay,et al.  A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. , 2007, Bone.

[14]  J. Reginster,et al.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club , 2010, Osteoporosis International.

[15]  J. Reginster,et al.  Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. , 2004, Bone.

[16]  T. Keaveny,et al.  Femoral strength in osteoporotic women treated with teriparatide or alendronate. , 2012, Bone.

[17]  Martha Timmer,et al.  Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis , 2007, Annals of Internal Medicine.

[18]  J. Reginster,et al.  Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  A. Maghraoui,et al.  Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice , 2005, Osteoporosis International.

[20]  Michael Wagener,et al.  Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Testa,et al.  Reproducibility of DXA absorptiometry: A model for bone loss estimates , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[23]  S. Majumdar,et al.  Teriparatide in Bisphosphonate-Resistant Osteoporosis: Microarchitectural Changes and Clinical Results After 6 and 18 months , 2011, Calcified Tissue International.

[24]  B. Dijkmans,et al.  Reproducibility of bone mineral density measurement in daily practice , 2004, Annals of the rheumatic diseases.

[25]  Eric Orwoll,et al.  Epidemiology of rib fractures in older men: Osteoporotic Fractures in Men (MrOS) prospective cohort study , 2010, BMJ : British Medical Journal.

[26]  S. Cummings,et al.  Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial , 2005, Osteoporosis International.

[27]  Dieter Felsenberg,et al.  Risedronate prevents new vertebral fractures in postmenopausal women at high risk. , 2003, The Journal of clinical endocrinology and metabolism.

[28]  S. Boonen,et al.  Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  S. Cummings,et al.  Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. , 1992, Annals of internal medicine.

[30]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  A. Silman,et al.  Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  S. Adami,et al.  Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  P. Geusens,et al.  Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[35]  M. Hochberg,et al.  Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial , 2002, Journal of the American Geriatrics Society.

[36]  D. Bauer,et al.  Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data , 2009, BMJ : British Medical Journal.

[37]  O. Johnell,et al.  Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture , 2001, Osteoporosis International.

[38]  J. Kanis.  TREATMENT OF OSTEOPOROTIC FRACTURE , 1984, The Lancet.

[39]  N. Freemantle,et al.  Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.

[40]  S. Cummings,et al.  Effects of antiresorptive treatment on nonvertebral fracture outcomes , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  A. Silman,et al.  Predictive value of BMD for hip and other fractures (Journal of Bone and Mineral Research (2005) 20, (1185-1194)) , 2007 .

[42]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.